SINTX Technologies Inc (SINT) shares experienced a dramatic surge of 91.5% to $5.40 on Monday, fueled by the news of a Notice of Allowance from the U.S. Patent and Trademark Office for their patent on zirconia-toughened alumina surface functionalization methods. This groundbreaking patent covers methods for bonding bioactive silicon nitride, or a mixture of silicon nitride and bioactive glass, to zirconia-toughened alumina (ZTA) surfaces.
The significance of this technology lies in its potential to enhance medical implants. By integrating silicon nitride’s exceptional properties, such as improved osseointegration (the process of bone bonding to an implant) and enhanced bacterial resistance, into the traditionally inert ZTA substrates commonly used in medical device manufacturing, SINTX aims to revolutionize implant performance.
Eric K. Olson, President and CEO of SINTX, expressed his enthusiasm, stating that the patent allowance signifies significant progress in the company’s intellectual property portfolio and strengthens their commitment to developing innovative biomaterials for medical applications.
SINTX proudly distinguishes itself as the sole FDA-registered producer of implantable silicon nitride. Furthermore, they have recently introduced a particulate form of this material, which can be utilized in composites and coatings, further expanding their product offerings and market reach.
The company’s focus on developing biocompatible and bioresorbable materials positions SINTX as a key player in the rapidly growing field of medical device manufacturing. The recent patent approval serves as a testament to their commitment to innovation and their potential to disrupt the traditional medical device landscape. Investors are closely watching SINTX’s progress as they strive to establish their technology as a standard in the industry.
